Brokerages Set InMode Ltd. (NASDAQ:INMD) Target Price at $18.54

InMode Ltd. (NASDAQ:INMD - Get Free Report) has been assigned an average recommendation of "Hold" from the eight analysts that are currently covering the company, Marketbeat.com reports. Seven analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average 12 month price target among analysts that have covered the stock in the last year is $18.54.

INMD has been the topic of a number of analyst reports. Jefferies Financial Group reduced their target price on shares of InMode from $16.00 to $15.00 and set a "hold" rating on the stock in a research note on Monday, April 14th. Robert W. Baird lowered shares of InMode from an "outperform" rating to a "neutral" rating and reduced their price target for the company from $22.00 to $16.00 in a research report on Monday, April 28th. Barclays lowered their price objective on InMode from $29.00 to $24.00 and set an "overweight" rating for the company in a research report on Wednesday, April 30th. UBS Group reduced their target price on InMode from $19.00 to $16.25 and set a "neutral" rating on the stock in a research report on Tuesday, April 29th. Finally, Baird R W cut InMode from a "strong-buy" rating to a "hold" rating in a report on Monday, April 28th.

Hedge Funds Weigh In On InMode

A number of hedge funds and other institutional investors have recently bought and sold shares of INMD. CWM LLC boosted its position in InMode by 106.4% in the 1st quarter. CWM LLC now owns 2,369 shares of the healthcare company's stock valued at $42,000 after buying an additional 1,221 shares during the period. Orion Capital Management LLC acquired a new stake in shares of InMode in the fourth quarter valued at $65,000. Summit Securities Group LLC purchased a new position in InMode in the first quarter valued at $70,000. SBI Securities Co. Ltd. acquired a new position in InMode during the 4th quarter worth $87,000. Finally, Farther Finance Advisors LLC increased its holdings in InMode by 26.2% during the 4th quarter. Farther Finance Advisors LLC now owns 5,555 shares of the healthcare company's stock worth $93,000 after purchasing an additional 1,154 shares during the period. 68.04% of the stock is currently owned by hedge funds and other institutional investors.

InMode Trading Up 2.7%

INMD stock traded up $0.38 during mid-day trading on Friday, reaching $14.61. The company's stock had a trading volume of 635,477 shares, compared to its average volume of 1,186,091. The company's 50 day moving average is $15.52 and its two-hundred day moving average is $17.17. InMode has a fifty-two week low of $13.68 and a fifty-two week high of $19.85. The stock has a market cap of $923.48 million, a PE ratio of 6.20 and a beta of 2.02.

InMode (NASDAQ:INMD - Get Free Report) last released its quarterly earnings data on Monday, April 28th. The healthcare company reported $0.31 earnings per share for the quarter, missing analysts' consensus estimates of $0.45 by ($0.14). InMode had a return on equity of 18.25% and a net margin of 45.91%. The company had revenue of $77.87 million for the quarter, compared to analyst estimates of $82.21 million. During the same period last year, the firm posted $0.32 EPS. The business's quarterly revenue was down 3.0% on a year-over-year basis. On average, analysts forecast that InMode will post 1.75 earnings per share for the current fiscal year.

InMode Company Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.